share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中進醫療 | 6-K:外國發行人報告
美股SEC公告 ·  2024/05/14 16:18

Moomoo AI 已提取核心訊息

Jin Medical International Ltd. has successfully regained compliance with Nasdaq's periodic filing requirements after submitting its annual report for the fiscal year 2023. The company had previously received a notice from Nasdaq on March 28, 2024, stating that it must file the report by May 20, 2024, to maintain its listing. The annual report was filed on April 26, 2024, and on May 9, 2024, Nasdaq confirmed the company's compliance. However, Nasdaq will continue to monitor Jin Medical International's adherence to the filing rule until May 9, 2025, and any future non-compliance during this period will lead directly to a delisting determination without the opportunity for the company to submit a new compliance plan.
Jin Medical International Ltd. has successfully regained compliance with Nasdaq's periodic filing requirements after submitting its annual report for the fiscal year 2023. The company had previously received a notice from Nasdaq on March 28, 2024, stating that it must file the report by May 20, 2024, to maintain its listing. The annual report was filed on April 26, 2024, and on May 9, 2024, Nasdaq confirmed the company's compliance. However, Nasdaq will continue to monitor Jin Medical International's adherence to the filing rule until May 9, 2025, and any future non-compliance during this period will lead directly to a delisting determination without the opportunity for the company to submit a new compliance plan.
Jin Medical International Ltd.在提交2023財年的年度報告後,成功恢復了對納斯達克定期申報要求的遵守。該公司此前曾於2024年3月28日收到納斯達克的通知,稱必須在2024年5月20日之前提交報告以維持其上市。該年度報告於2024年4月26日提交,2024年5月9日,納斯達克確認了該公司的合規性。但是,納斯達克將在2025年5月9日之前繼續監督Jin Medical International對申報規則的遵守情況,在此期間的任何違規行爲都將直接導致退市決定,該公司沒有機會提交新的合規計劃。
Jin Medical International Ltd.在提交2023財年的年度報告後,成功恢復了對納斯達克定期申報要求的遵守。該公司此前曾於2024年3月28日收到納斯達克的通知,稱必須在2024年5月20日之前提交報告以維持其上市。該年度報告於2024年4月26日提交,2024年5月9日,納斯達克確認了該公司的合規性。但是,納斯達克將在2025年5月9日之前繼續監督Jin Medical International對申報規則的遵守情況,在此期間的任何違規行爲都將直接導致退市決定,該公司沒有機會提交新的合規計劃。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息